Trial Profile
A Multicenter single arm Phase II clinical trial of the second-line treatment with FOLFIRI plus panitumumab after failure of the first-line treatment with FOLFOX plus panitumumab for advanced and/or recurrent RAS wild-type colorectal cancer with special reference to the changes in biomarker expression examined by a liquid biopsy and its effect on the refractory tumor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms PBP
- 01 Nov 2022 Status has been changed to completed, as per Results published in the International Journal of Cancer
- 01 Nov 2022 Results published in the International Journal of Cancer
- 06 Aug 2018 Status changed from not yet recruiting to recruiting.